Shire PLC Receives Average Rating of “Buy” from Analysts (LON:SHP)
Shire PLC (LON:SHP) has received an average recommendation of “Buy” from the twenty-six ratings firms that are covering the company, AmericanBankingNews.com reports. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is GBX 3,683.43 ($61.98).
SHP has been the subject of a number of recent research reports. Analysts at Sanford C. Bernstein reiterated a “market perform” rating on shares of Shire PLC in a research note on Friday, July 25th. They now have a GBX 5,300 ($89.18) price target on the stock. Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of Shire PLC in a research note on Monday, July 21st. They now have a GBX 5,200 ($87.50) price target on the stock. Finally, analysts at Kepler Capital Markets reiterated a “buy” rating on shares of Shire PLC in a research note on Tuesday, July 15th. They now have a GBX 5,100 ($85.82) price target on the stock.
Shares of Shire PLC (LON:SHP) opened at 4904.00 on Monday. Shire PLC has a one year low of GBX 2356.00 and a one year high of GBX 5050.00. The stock has a 50-day moving average of GBX 4548.22 and a 200-day moving average of GBX 3539.. The company’s market cap is £28.757 billion.
The company also recently declared a dividend, which is scheduled for Friday, October 3rd. Stockholders of record on Wednesday, September 3rd will be given a dividend of GBX 2.24 ($0.04) per share. This represents a yield of 0.04%. The ex-dividend date of this dividend is Wednesday, September 3rd.
Shire plc (LON:SHP) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.